ProShare Advisors LLC purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,017,893 shares of the company’s stock, valued at approximately $9,568,000. ProShare Advisors LLC owned approximately 0.21% of Elanco Animal Health as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of ELAN. JPMorgan Chase & Co. boosted its holdings in Elanco Animal Health by 15.6% in the first quarter. JPMorgan Chase & Co. now owns 355,004 shares of the company’s stock worth $9,262,000 after purchasing an additional 47,881 shares in the last quarter. American Century Companies Inc. boosted its holdings in Elanco Animal Health by 11.8% in the first quarter. American Century Companies Inc. now owns 32,218 shares of the company’s stock worth $841,000 after purchasing an additional 3,396 shares in the last quarter. US Bancorp DE boosted its position in Elanco Animal Health by 17.5% during the first quarter. US Bancorp DE now owns 16,263 shares of the company’s stock worth $425,000 after purchasing an additional 2,419 shares during the period. Private Advisor Group LLC bought a new stake in Elanco Animal Health during the first quarter worth approximately $333,000. Finally, MetLife Investment Management LLC bought a new stake in Elanco Animal Health during the first quarter worth approximately $232,000. 95.29% of the stock is currently owned by institutional investors.
Elanco Animal Health Price Performance
NYSE:ELAN opened at $11.99 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.84 and a quick ratio of 1.53. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $14.85. The company has a fifty day moving average price of $11.81 and a 200 day moving average price of $10.26. The stock has a market cap of $5.91 billion, a P/E ratio of -59.95, a PEG ratio of 7.78 and a beta of 1.01.
Wall Street Analyst Weigh In
ELAN has been the subject of a number of recent analyst reports. Piper Sandler upped their target price on Elanco Animal Health from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, August 14th. The Goldman Sachs Group raised their price target on Elanco Animal Health from $8.50 to $9.50 and gave the company a “sell” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $15.10.
Check Out Our Latest Analysis on Elanco Animal Health
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
See Also
- Five stocks we like better than Elanco Animal Health
- Airline Stocks – Top Airline Stocks to Buy Now
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- How to Invest in E-Commerce: A Guide
- MarketBeat Week in Review – 9/11 – 9/15
- 10 Best Airline Stocks to Buy
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
